重组人B型钠尿肽联合尼可地尔治疗急性心力衰竭的临床效果

Clinical Effect of Recombinant Human Natriuretic Peptides B Combined with Nicorandil in the Treatment of Acute Heart Failure

目的:探讨重组人B型钠尿肽联合尼可地尔治疗急性心力衰竭(AHF)的临床效果。方法:选取2022年2月—2023年5月单县中心医院急诊科收治的AHF患者117例作为研究对象,采用随机数字表法将其分为对照组(58例)和观察组(59例)。对照组采用尼可地尔治疗,观察组在对照组基础上采用重组人B型钠尿肽治疗。比较两组患者治疗效果、心功能、血管内皮指标及不良反应发生率。结果:观察组治疗效果总有效率高于对照组,差异有统计学意义(P=0.026);治疗后,两组左室射血分数(LVEF)高于治疗前,左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)低于治疗前,且观察组LVEF高于对照组,LVEDD、LVESD低于对照组,差异有统计学意义(P<0.05);治疗后,两组内皮素-1(ET-1)低于治疗前,一氧化氮(NO)水平高于治疗前,且观察组ET-1水平低于对照组,NO水平高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:AHF患者应用重组人B型钠尿肽联合尼可地尔治疗,能更好地调节血管内皮功能,改善心功能,疗效与安全性较理想。

Objective:To investigate the clinical effect of Recombinant Human Natriuretic Peptides B combined with nicorandil in the treatment of acute heart failure(AHF).Methods:117 patients with AHF admitted to the emergency department of Shanxian Central Hospital from February 2022 to May 2023 were selected as the study subjects,and they were divided into the control group(58 cases)and the observation group(59 cases)by using the method of randomized numerical table.The control group was treated with nicorandil,and the observation group was treated with Recombinant Human Natriuretic Peptides B on the basis of the control group.The therapeutic effect,cardiac function,vascular endothelial indexes and the incidence of adverse reactions in the two groups were compared.Results:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P=0.026);After treatment,the left ventricular ejection fraction(LVEF)of the two groups was higher than that before treatment,and the left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were lower than those before treatment,and the LVEF of the observation group was higher than that of the con⁃trol group,while the LVEDD and LVESD were lower than those of the control group,and the difference was statistically significant(P<0.05);After treatment,endothelin-1(ET-1)was lower than that before treatment while nitric oxide(NO)level was higher than that before treatment in both groups,and ET-1 level in the observation group was lower than that in the control group,and NO level was higher than that in the control group,and the difference was statistically significant(P<0.05);when comparing the inci⁃dence rates of adverse reactions in the two groups,the difference was not statistically significant(P>0.05).Conclusion:The admin⁃istration of Recombinant Human Natriuretic Peptides B combined with nicorandil in patients with AHF can better regulate the vas⁃cular endothelial function and improve the cardiac function,and their efficacy and safety are satisfactory.